HNW005

HNW005 is a dual inhibitor of NLRP3 inflammasome and urate transporter 1 (URAT1) . It has a KD value of 204.6 nM and an IC50 of 1.7 μM for inhibiting NLRP3 inflammasome activation, and an IC50 of 6.4 μM for inhibiting uric acid transmembrane transport. When administered at a dose of 2 mg/kg in vivo, HNW005 can achieve a uric acid reduction rate of 64.8%. It can exert anti - inflammatory, analgesic, and uric acid - lowering activities by inhibiting the activation of NLRP3 inflammasome and uric acid transmembrane transport. HNW005 can be used in the research of gouty arthritis[1].

Product Specifications

UNSPSC

12352005

Target

NOD-like Receptor (NLR) ; URAT1

Related Pathways

Immunology/Inflammation; Membrane Transporter/Ion Channel

Field of Research

Metabolic Disease; Inflammation/Immunology

Smiles

O=C(NC1=CC=CC=C1C(O)=O)C2=NNC(C3=CC=C(C(F)(F)F)C=C3)=C2

Molecular Formula

C18H12F3N3O3

Molecular Weight

375.30

References & Citations

[1]Sun M, et al. Scaffold hopping-based structural modification of tranilast led to the identification of HNW005 as a promising NLRP3 inflammasome and URAT1 dual inhibitor for the treatment of gouty arthritis. Eur J Med Chem. 2025 Apr 17;292:117644.